Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Sep 18, 2020: MATINS trial data presented at ESMO
Press releases — page 7
MATINS trial data presented at ESMO
September 18, 2020
Traumakine Update
August 18, 2020
Change of Adviser
July 27, 2020
Managers' transactions
July 8, 2020
Faron hosts virtual R&D Day today
June 16, 2020
Faron receives EUR 2.1 million funding from BF
June 15, 2020
Faron selected for EUR2.5 million grant from EIC
June 11, 2020
MATINS Update
June 1, 2020
Faron announces R&D Day to be held in June
May 28, 2020
Publication in Intensive Care Medicine
May 20, 2020
Faron receives grant from Business Finland
May 11, 2020
Clevegen manufacturing agreement
May 5, 2020
Traumakine to be a part of WHO's Solidarity trial
April 27, 2020
Update on results of Placing and issue of equity
April 23, 2020
Result of placing and issue price
April 22, 2020
Proposed Placing
April 21, 2020
AGM to be postponed
April 3, 2020
REMAP-CAP to study IFN beta-1a effect in COVID-19
April 1, 2020
Part 1 of the MATINS Phase I/II Study Completed
March 30, 2020
Correction to Faron´s Annual Report 2019
March 26, 2020
Faron´s Annual Report 2019 published
March 25, 2020
Final Results for the year ended December 31, 2019
March 20, 2020
FDA accepts protocol for new Traumakine trial
March 9, 2020
MATINS update
March 5, 2020
Faron to acquire AOC3 antagonist platform
March 2, 2020
Traumakine update
February 6, 2020
Ovarian cancer selected as 2nd MATINS trial cohort
January 27, 2020
DMC approves colorectal cancer cohort expansion
January 13, 2020
Update on Traumakine drug substance manufacturing
December 30, 2019
Matins Trial Update
December 11, 2019
LIQUIDITY PROVIDING AGREEMENT
November 29, 2019
FDA has approved Faron's Clevegen IND
November 28, 2019
Faron´s financial calendar for 2020
November 27, 2019
Application to Nasdaq First North Growth Market
November 21, 2019
Registration of Shares
November 12, 2019
Results of Placing and Issue Price
November 8, 2019
Proposed Placing and Financial Adviser Appointment
November 7, 2019
Statement regarding Price Movement
November 1, 2019
MATINS poster presentation at ESMO Congress
September 30, 2019
Interim results
September 23, 2019
MATINS study selected for ESMO 2019
September 2, 2019
Result of Open Offer and Further Subscription
August 27, 2019
Notice of Interim Results
August 16, 2019
Subscription and Open Offer
August 5, 2019
MATINS study update
July 12, 2019
Phase II INFORAAA study update
June 26, 2019
Final results from YODA study
June 14, 2019
AGM update, Board & management changes
May 24, 2019
Share Subscription and Issue of Equity
May 14, 2019
Notice of AGM
May 7, 2019